Pharmaids Pharmaceuticals Ltd. (PHARMAID): Pharmaids Pharmaceuticals Share Price Rises 8.39% Today

Pharmaids Pharmaceuticals Share Price rises 8.39% today to Rs 34.9, with a market cap of Rs 114.66 crore.

Pharmaids Pharmaceuticals Share Price has seen a notable increase today, rising by 8.39% to reach Rs 34.9. This significant gain places the company in the spotlight within the micro-cap category, where it currently holds a market capitalisation of Rs 114.66 crore.

Today's price movement is significant for Pharmaids Pharmaceuticals, a company operating in the Healthcare sector, specifically within the Pharmaceuticals & Drugs industry. The increase in share price is a key event for investors tracking the stock, as it reflects a positive shift in market sentiment. While the data confirms the price rise, it does not establish a specific company-related catalyst for this movement.

Pharmaids Pharmaceuticals Ltd. (PHARMAID) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 34.9
Previous Close	Rs 32.2
Today's Change	+Rs 2.7 (+8.39%)
Day Open	Rs 33.14
Day High	Rs 36.04
Day Low	Rs 33.05
Current Volume (BSE)	19,298
BSE Traded Volume	19,298
Combined NSE + BSE Volume	19,298
Turnover	Rs 0.07 crore
Market Capitalisation	Rs 114.66 crore
Market Cap Category	Micro Cap

Pharmaids Pharmaceuticals Ltd. (PHARMAID) traded at Rs 34.9. versus the previous close of Rs 32.2, a rise of 8.39%. The stock opened at Rs 33.14, reached Rs 36.04, touched Rs 33.05. Reported volume was 19,298.

Pharmaids Pharmaceuticals Ltd. (PHARMAID) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 114.66 crore
P/E Ratio	-10.51x
P/B Ratio	2.38x
ROE	1.1%
ROCE	1.04%
EPS	Rs -3.32
Dividend Yield	0%

Pharmaids Pharmaceuticals Ltd. was valued at a P/E ratio of -10.51x, a P/B ratio of 2.38x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 1.1% and ROCE of 1.04%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs -3.32, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Pharmaids Pharmaceuticals, with a market capitalisation of Rs 114.66 crore, operates within the Healthcare sector. The company's financial metrics provide a mixed picture of its current valuation and performance. The P/E ratio stands at -10.51, indicating that the company is currently not profitable, as earnings per share (EPS) is -3.32. This negative EPS reflects a challenging financial position.

The P/B ratio is 2.38, which is above the industry median of 1.86, suggesting that the stock may be valued higher relative to its book value compared to its peers. The return on equity (ROE) is 1.1%, and the return on capital employed (ROCE) is 1.04%, both of which are below the industry averages, indicating lower profitability and efficiency.

Pharmaids Pharmaceuticals does not offer a dividend yield, which may be a consideration for income-focused investors. The company's current financial performance highlights the need for careful evaluation of its growth prospects and market positioning.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	-10.51x
Benchmark Median P/E	26.22x
Benchmark Average P/E	81.19x
Benchmark P/E Range	3.23x to 3,428.55x
Company P/B Ratio	2.38x
Benchmark Median P/B	1.86x
Company ROE	1.1%
Benchmark Median ROE	10.59%
Company ROCE	1.04%
Benchmark Median ROCE	12.98%
Company Market Capitalisation	Rs 114.66 crore
Benchmark Median Market Cap	Rs 145.72 crore

Pharmaids Pharmaceuticals Ltd. (PHARMAID) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Pharmaids Pharmaceuticals Ltd. (PHARMAID) has a P/E ratio of -10.51x, which is below the benchmark median of 26.22x, a difference of -140.08%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Pharmaids Pharmaceuticals Ltd. (PHARMAID) has a ROE of 1.1%, which is below the benchmark median of 10.59%, a difference of -89.61%. Pharmaids Pharmaceuticals Ltd. (PHARMAID) has a ROCE of 1.04%, which is below the benchmark median of 12.98%, a difference of -91.99%.

Track today's top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

The P/B ratio of 2.38 is slightly above the industry median of 1.86, suggesting a higher valuation relative to book value. The company's ROE of 1.1% and ROCE of 1.04% are both below the industry averages, reflecting lower returns on equity and capital employed.

With a market cap of Rs 114.66 crore, Pharmaids Pharmaceuticals is positioned below the industry median of Rs 145.72 crore. This places the company in the lower range of the market-cap spectrum within its industry, highlighting the competitive landscape it operates in.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	2,943.6	31.4	0.46	-2.89	-0.26
Hikal Ltd.	HIKAL	2,812.49	0	2.39	15.22	16.15
Kwality Pharmaceuticals Ltd.	KPL	2,684.11	39.39	8.02	28.21	26.35
Beta Drugs Ltd.	BETA	2,621.81	63.25	10.01	18.65	22.17
Panacea Biotec Ltd.	PANACEABIO	2,566.71	0	3.08	0	5.36

Pharmaids Pharmaceuticals Ltd. (PHARMAID) has a P/E ratio of -10.51x compared with the displayed peer median of 31.4x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 1.1% compares with a peer median of 15.22% across the companies shown in the table. ROCE stood at 1.04% versus the displayed peer median of 16.15%, providing a capital-efficiency comparison. Pharmaids Pharmaceuticals Ltd. (PHARMAID) has a market capitalisation of Rs 114.66 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

In comparison to its peers, Pharmaids Pharmaceuticals shows distinct differences in financial metrics. Dishman Carbogen Amcis Ltd. has a P/E of 31.4, while Pharmaids' P/E is -10.51, indicating a lack of profitability. Hikal Ltd. has a P/B of 2.39, similar to Pharmaids' 2.38, but with stronger ROE and ROCE figures.

Kwality Pharmaceuticals Ltd. and Beta Drugs Ltd. both exhibit higher P/E ratios and ROE, indicating stronger financial performance. These comparisons highlight the challenges Pharmaids Pharmaceuticals faces in achieving profitability and improving its financial metrics relative to its peers.

Why Investors Are Watching Pharmaids Pharmaceuticals

Investors are closely monitoring Pharmaids Pharmaceuticals due to its recent price rise and market activity. The stock's performance today has drawn attention, and several factors are contributing to this interest:

• Price Action: Significant 8.39% rise in share price today.
• Technical Position: RSI indicates weak momentum, suggesting cautious optimism.
• Fundamental Context: Negative EPS and low ROE highlight financial challenges.
• Sector Positioning: Operates in a competitive Pharmaceuticals & Drugs industry.

Investors should continue to monitor Pharmaids Pharmaceuticals for any developments that may impact its financial performance and market position. The company's ability to improve profitability and strengthen its market presence will be key factors to watch.

About Pharmaids Pharmaceuticals

Pharmaids Pharmaceuticals Ltd. operates in the Healthcare sector, focusing on the Pharmaceuticals & Drugs industry. The company is involved in the development, manufacturing, and distribution of pharmaceutical products. Its product portfolio includes a range of drugs and formulations aimed at addressing various medical needs.

As a micro-cap company, Pharmaids Pharmaceuticals faces challenges in scaling its operations and achieving profitability. The competitive landscape of the Pharmaceuticals & Drugs industry requires continuous innovation and strategic positioning to capture market share.

Despite its current financial challenges, Pharmaids Pharmaceuticals remains a player in the industry, with potential opportunities for growth and expansion in the future.

Track Pharmaids Pharmaceuticals Share Price on Univest

Use Pharmaids Pharmaceuticals Ltd. (PHARMAID) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors can track the Pharmaids Pharmaceuticals Share Price on Univest for real-time updates and insights. Univest provides access to live share prices, technical indicators, fundamental ratios, and shareholding patterns. Stay informed about the latest market trends and developments by following Pharmaids Pharmaceuticals on Univest.

Frequently Asked Questions

What is the current share price of Pharmaids Pharmaceuticals?

Ans. The current share price of Pharmaids Pharmaceuticals is Rs 34.9, reflecting an 8.39% increase from the previous close of Rs 32.2. The stock moved 8.39% during the session. The intraday range extended from Rs 33.05 to Rs 36.04.

How much did Pharmaids Pharmaceuticals' share price rise today?

Ans. Pharmaids Pharmaceuticals' share price rose by 8.39% today, marking a significant gain in the micro-cap category. The stock moved 8.39% during the session. The intraday range extended from Rs 33.05 to Rs 36.04.

What is the market capitalisation of Pharmaids Pharmaceuticals?

Ans. Pharmaids Pharmaceuticals has a market capitalisation of Rs 114.66 crore, positioning it within the micro-cap category. The company operates in the Healthcare sector. Its P/E ratio is -10.51x. ROE is 1.1% and ROCE is 1.04%.

What is the P/E ratio of Pharmaids Pharmaceuticals?

Ans. The P/E ratio of Pharmaids Pharmaceuticals is -10.51, indicating that the company is currently not profitable. The company trades at a P/E ratio of -10.51x. Its P/B ratio is 2.38x.

What is the P/B ratio of Pharmaids Pharmaceuticals?

Ans. The P/B ratio of Pharmaids Pharmaceuticals is 2.38, which is above the industry median of 1.86. The company trades at a P/E ratio of -10.51x. Its P/B ratio is 2.38x.

How does Pharmaids Pharmaceuticals' ROE compare to the industry?

Ans. Pharmaids Pharmaceuticals' ROE is 1.1%, which is below the industry median of 10.59%, indicating lower profitability. ROE stands at 1.1%. ROCE stands at 1.04%. The relevant peer median ROE is 10.59%.

How does Pharmaids Pharmaceuticals' market cap compare to its peers?

Ans. Pharmaids Pharmaceuticals' market cap of Rs 114.66 crore is below the industry median of Rs 145.72 crore, highlighting its position in the micro-cap category. The company operates in the Healthcare sector.